Osamu Tanaka

Osamu Tanaka

Auto-generated profile, based on publicly available information

Osamu Tanaka

Department of Radiation Oncology, Asahi University Hospital, 3-23 Hashimoto-cho, Gifu City, Gifu 500-8523, Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2006 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
OTOsamu Tanaka
Osamu Tanaka
SHShinya Hayashi
Shinya Hayashi
MMMasayuki Matsuo
Masayuki Matsuo
KSKota Sakurai
Kota Sakurai
MNMasahiro Nakano
Masahiro Nakano
HHHiroaki Hoshi
Hiroaki Hoshi

1 October 2007 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
OTOsamu Tanaka
Osamu Tanaka
SHShinya Hayashi
Shinya Hayashi
MMMasayuki Matsuo
Masayuki Matsuo
MNMasahiro Nakano
Masahiro Nakano
HUHiromi Uno
Hiromi Uno
HHHiroaki Hoshi
Hiroaki Hoshi

1 November 2005 in Journal of Thoracic Imaging
Verified
Journal Article
Closed access
OTOsamu Tanaka
Osamu Tanaka
TKTakuji Kiryu
Takuji Kiryu
Yoshinobu HiroseYoshinobu Hirose
Yoshinobu Hirose
HIHisashi Iwata
Hisashi Iwata
HHHiroaki Hoshi
Hiroaki Hoshi
Various histologic types of neurogenic tumors may originate in the mediastinum and chest wall. It is possible to make accurate diagnosis of these tumors by using the multiplanar capability and high contrast resolution of MR imaging because of these characteristic imaging findings. MR and histologic features of these tumors are illustrated and described in this essay.

1 April 2006 in Brachytherapy
Verified
Journal Article
Closed access
MNMasahiro Nakano
Masahiro Nakano
HUHiromi Uno
Hiromi Uno
TGTakahiro Gotoh
Takahiro Gotoh
YKYasuaki Kubota
Yasuaki Kubota
SISatoshi Ishihara
Satoshi Ishihara
HHHiroaki Hoshi
Hiroaki Hoshi

11 May 2020 in British Journal of Radiology
Verified
Journal Article
Closed access
OTOsamu Tanaka
Osamu Tanaka
ASAkihiko Sugiyama
Akihiko Sugiyama
TOTatsushi Omatsu
Tatsushi Omatsu
MTMasahiro Tawada
Masahiro Tawada
CMChiyoko Makita
Chiyoko Makita
MMMasayuki Matsuo
Masayuki Matsuo
Objective: Standard treatment for progressive gastric cancer with bleeding includes hemostatic radiotherapy (RT); however, the only prospective study using a fixed dose with fractions during hemostatic RT did not introduce re-irradiation. Therefore, we determined the utility of RT including re-irradiation for gastric cancer. Methods: In this study, 31 patients with gastric cancer and bleeding were treated with an initial dose of 20 Gy/5 fractions for the whole stomach and a salvage dose of 15 Gy/5 fractions for the partial stomach. Patients achieving hemostasis, defined as a stable hemoglobin level within 30 days following irradiation, were considered responders, whereas those with no cessation of bleeding and those with re-bleeding within 30 days of irradiation were considered non-responders. We evaluated response rate, disease-free survival, overall survival (OS), re-irradiation, and adverse events (AEs). Results: The response rate of initial RT was 80% (25/31). 6 of the 25 patients underwent re-irradiation, and all 6 were responders (100%). The median OS was significantly different among the entire cohort and one-time irradiation and re-irradiation groups (91, 76, and 112 days, respectively). No AEs of grade ≥3 were observed. Initial low-dose RT followed by reirradiation was effective in reducing AEs and did not cause any further AEs. Conclusion: Hemostatic RT was an effective approach with low toxicity, and re-irradiation was effective and tolerable, with no patients developing severe AEs. Further, randomized controlled studies are warranted to determine the ideal dose and number of fractions for initial RT in patients with gastric cancer and bleeding. Advances in knowledge: In this prospective study on hemostatic radiotherapy for gastric cancer, the response rate was 80% using a fixed dose of 20 Gy/5 fractions and the salvage dose of 15 Gy for re-bleeding was effective. Future comparative studies should include other doses with 20 Gy as a control.

1 February 1993 in Brain Structure and Function
Verified
Journal Article
Closed access
PDF file
HOHiroki Otani
Hiroki Otani
TYTsunao Yoneyama
Tsunao Yoneyama
RHRyuju Hashimoto
Ryuju Hashimoto
THToshihisa Hatta
Toshihisa Hatta
OTOsamu Tanaka
Osamu Tanaka